Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(33%)
Results Posted
0%(0 trials)
Terminated
1(11%)

Phase Distribution

Ph not_applicable
3
33%
Ph phase_3
1
11%
Ph phase_4
4
44%

Phase Distribution

0

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
4(50.0%)
N/ANon-phased studies
3(37.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(5)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Recruiting2
Not yet recruiting2
Withdrawn1
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (12.5%)
Phase 44 (50.0%)
N/A3 (37.5%)

Trials by Status

completed222%
recruiting222%
withdrawn111%
terminated111%
not_yet_recruiting222%
active_not_recruiting111%

Recent Activity

3 active trials
Showing 5 of 9
recruiting

Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease

NCT07504510
active_not_recruitingnot_applicable

Exclusive Enteral Nutrition in Preterm Neonates

NCT04337710
recruitingnot_applicable

Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.

NCT06912815
not_yet_recruitingphase_4

Combined Application of EEN in the Induction of Remission in PUC

NCT04999241
completedphase_4

Top-down Infliximab Study in Kids With Crohn's Disease

NCT02517684
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07504510

Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease

Recruiting
NCT04337710Not Applicable

Exclusive Enteral Nutrition in Preterm Neonates

Active Not Recruiting
NCT06912815Not Applicable

Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.

Recruiting
NCT04999241Phase 4

Combined Application of EEN in the Induction of Remission in PUC

Not Yet Recruiting
NCT02517684Phase 4

Top-down Infliximab Study in Kids With Crohn's Disease

Completed
NCT04530877Phase 4

Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients

Withdrawn
NCT03833596Phase 4

Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD)

Terminated
NCT04398836Phase 3

Preoperative Nutrition for Crohn's Disease Patients

Not Yet Recruiting
NCT03755583Not Applicable

Effect of Exclusive Enteral Nutrition on Disease Process, Nutritional Status and Gastrointestinal Microbiota for Chinese Children With Crohn's Disease

Completed

All 9 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
9